338 related articles for article (PubMed ID: 32448602)
21. Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors.
Reddy S; Tatiparti K; Sau S; Iyer AK
Drug Discov Today; 2021 Aug; 26(8):1944-1952. PubMed ID: 33865978
[TBL] [Abstract][Full Text] [Related]
22. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicine for glioblastoma: Progress and future prospects.
Khan I; Baig MH; Mahfooz S; Imran MA; Khan MI; Dong JJ; Cho JY; Hatiboglu MA
Semin Cancer Biol; 2022 Nov; 86(Pt 2):172-186. PubMed ID: 35760272
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Potential of Nanomedicine in Management of Alzheimer's Disease and Glioma.
Anwar F; Al-Abbasi FA; Naqvi S; Sheikh RA; Alhayyani S; Asseri AH; Asar TO; Kumar V
Int J Nanomedicine; 2023; 18():2737-2756. PubMed ID: 37250469
[TBL] [Abstract][Full Text] [Related]
25. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
26. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
28. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
29. Cnf1 Variants Endowed with the Ability to Cross the Blood-Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma.
Colarusso A; Maroccia Z; Parrilli E; Germinario EAP; Fortuna A; Loizzo S; Ricceri L; Tutino ML; Fiorentini C; Fabbri A
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32375387
[TBL] [Abstract][Full Text] [Related]
30. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.
Upadhaya PG; Pulakkat S; Patravale VB
Drug Deliv Transl Res; 2020 Aug; 10(4):1044-1056. PubMed ID: 32221847
[TBL] [Abstract][Full Text] [Related]
31. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
32. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
33. Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M; van Straten D; Broekman MLD; Préat V; Schiffelers RM
Theranostics; 2020; 10(3):1355-1372. PubMed ID: 31938069
[TBL] [Abstract][Full Text] [Related]
34. Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.
Cesarini V; Scopa C; Silvestris DA; Scafidi A; Petrera V; Del Baldo G; Gallo A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32957732
[TBL] [Abstract][Full Text] [Related]
35. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
36. Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours.
Ferraris C; Cavalli R; Panciani PP; Battaglia L
Int J Nanomedicine; 2020; 15():2999-3022. PubMed ID: 32431498
[TBL] [Abstract][Full Text] [Related]
37. Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics.
Wang K; Zhang F; Wen C; Huang Z; Hu Z; Zhang Y; Hu F; Wen L
Oncol Res; 2021; 29(5):351-363. PubMed ID: 37305160
[TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme.
Pottoo FH; Javed MN; Rahman JU; Abu-Izneid T; Khan FA
Semin Cancer Biol; 2021 Feb; 69():391-398. PubMed ID: 32302695
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticle-based diagnostic and therapeutic systems for brain tumors.
Wu X; Yang H; Yang W; Chen X; Gao J; Gong X; Wang H; Duan Y; Wei D; Chang J
J Mater Chem B; 2019 Aug; 7(31):4734-4750. PubMed ID: 31389961
[TBL] [Abstract][Full Text] [Related]
40. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
